Title : Oral antiplatelet agents in cardiovascular disease.

Pub. Date : 2019 Jul

PMID : 30324870






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Moreover, vorapaxar allows the inhibition of platelet activation by thrombin via protease-activated receptor-1 and has been approved for the use in patients with PAD and in those with a history of myocardial infarction. vorapaxar coagulation factor II, thrombin Homo sapiens